Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Pharma Signs $165 Million Deal for ImmVira Oncolytic Virus Program

publication date: Aug 14, 2020

Shanghai Pharmaceuticals in-licensed China rights to an intratumoral oncolytic virus program developed by Shenzhen's ImmVira in an agreement worth up to $165 million. ImmVira's MVR-T3011 oncolytic virus program is aimed at developing novel immunotherapies for malignant solid tumors. MVR-T3011 is a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) designed to enhance the oncolytic effects of oHSV-1. Through gene recombinant technologies, the virus expresses PD-1 antibody and interleukin-12 immune modulators. More details....

Stock Symbols: (SHA: 601607; HK :02067)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.